Alfonso Quintás‐Cardama

Author

The University of Texas MD Anderson Cancer Center ORCID

Also Known As

A Quintas-Cardama, A Quintás-Cardama, A. Quintas-Cardama, A. Quintás-Cardama, AlFonso Quintas-Cardama, Alfonso Quintas-Cardama, Alfonso QuintasCardama, Alfonso Quintas‐Cardama, Alfonso Quintás-Cardama, Alfonso Quintás-Cardama

566

Publications

16.7K

Citations

H-Index

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center Baylor College of Medicine Memorial Sloan Kettering Cancer Center University of Michigan Mayo Clinic

About

Alfonso Quintás‐Cardama is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, hematology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	26	40	2.3K
2	Health Sciences	9	9	255
3	Engineering	1	1	71
4	Natural Sciences	1	1	131
5	Biochemistry	1	1	24

Alfonso Quintás‐Cardama

Publications

8.1K

Citations

H-Index

Page 1

	Year	Citations
Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms Alfonso Quintás‐Cardama, Kris Vaddi, Phillip Liu, Blood	2010	813
Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera Alfonso Quintás‐Cardama, Hagop M. Kantarjian, Taghi Manshouri, Journal of Clinical Oncology	2009	412
Pleural Effusion in Patients With Chronic Myelogenous Leukemia Treated With Dasatinib After Imatinib Failure Alfonso Quintás‐Cardama, Hagop M. Kantarjian, Susan O’Brien, Journal of Clinical Oncology	2007	388
Mutant FLT3: A Direct Target of Sorafenib in Acute Myelogenous Leukemia Weiguo Zhang, Marina Konopleva, Yue-Xi Shi, JNCI Journal of the National Cancer Institute	2008	338
Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience Hagop M. Kantarjian, Susan O’Brien, Elias Jabbour, Blood	2012	335
p53-Mediated Senescence Impairs the Apoptotic Response to Chemotherapy and Clinical Outcome in Breast Cancer James G. Jackson, Vinod Pant, Qin Li, Cancer Cell Breast OncologyLongevityMedicineApoptosisApoptotic Response	2012	327
Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia Alfonso Quintás‐Cardama, Farhad Ravandi, Theresa Liu-Dumlao, Blood	2012	219
Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a Alfonso Quintás‐Cardama, Omar Abdel‐Wahab, Taghi Manshouri, Blood	2013	205
Tyrosine kinase inhibitor–induced platelet dysfunction in patients with chronic myeloid leukemia Alfonso Quintás‐Cardama, Xin Han, Hagop M. Kantarjian, Blood	2009	203
The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up Ravin J. Garg, Hagop M. Kantarjian, Susan O’Brien, Blood	2009	164

Page 1